Sorry, your browser does not support JavaScript. Please enable for better viewing.
how technology works
48 million ADULTS ARE CLINICALLY
B12 DEFICIENT
WHO IS AT
GREATEST RISK?
    B12 DEFICIENCY
MAY CAUSE SERIOUS HEMATOLOGICAL
AND NEUROLOGICAL CONDITIONS.
Eligen B12 helps normalize B12 levels without inconvenient injections. Screen. Treat. Protect.
Your patients today.
  • Learn about the risks of low B12 and how Eligen B12 can help.

  • Your patients may be at greater risk for clinically low B12 levels.

    LEARN WHO IS AT RISK
  • Get more information about how Eligen B12 can help.

    Learn more
  • A prescription medical food is an FDA product classification. Medical foods are formulated to be consumed or administered orally under medical supervision and are intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements are established by medical evaluation. Eligen B12™ is a medical food available by prescription for patients who have a medically diagnosed vitamin B12 deficiency, associated with a disease or condition, that cannot be managed by a modification of normal diet alone.1,4
Intended for U.S. Residents Only
4 Becker Farm Road, Suite 103, Roseland NJ 07068
1-800-903-5028
April 2016 ELB034

Indication

Eligen B12™ is indicated for the dietary management of patients who have a diagnosed vitamin B12 deficiency that cannot be managed by a modification of the normal diet alone. This deficiency can be caused by a range of conditions in which there is an impaired capacity to absorb vitamin B12.

Important Safety Information

Eligen B12™ is contraindicated in patients with hypersensitivity to cobalt, vitamin B12 or any component of Eligen B12™.

Eligen B12™ is contraindicated in patients with hereditary optic nerve atrophy. Do not use in patients with early hereditary optic nerve atrophy (Leber’s disease). Treatment with vitamin B12 has resulted in severe and swift optic atrophy.

Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. No such reactions have been reported during limited clinical trials with Eligen B12™.

Hypokalemia and sudden death may occur in severe megaloblastic anemia treated intensely with vitamin B12. Folic acid is not a substitute for vitamin B12, although it may improve vitamin B12-deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B12-deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B12 may be due to such conditions as infection, uremia, use of drugs having bone marrow-suppressant properties (such as chloramphenicol), and concurrent iron or folic acid deficiency.

Vitamin B12 deficiency that is allowed to progress for longer than 3 months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg per day may result in hematologic remission in patients with vitamin B12 deficiency. Neurologic manifestations will not be prevented with folic acid; if not treated with vitamin B12, irreversible damage will result.

Doses of vitamin B12 exceeding 10 mcg a day may produce hematologic response in patients with folate deficiency. Vitamin B12 is not a substitute for folic acid, and indiscriminate use of vitamin B12 could mask the true diagnosis.

Vitamin B12 deficiency may suppress the sign of polycythemia vera. Treatment with vitamin B12 may unmask this condition.

No specific adverse reactions were identified during the limited studies with Eligen B12™.

It is not known whether vitamin B12 supplementation causes fetal harm or affects reproduction capacity when administered to a pregnant woman.

The safety and efficacy of Eligen B12™ have not been established in patients below the age of 18 years.